Conventional screening options for colorectal cancer (CRC) detection are mainly direct visualization and invasive methods, which must be performed in a clinical setting and may be linked to adverse effects for some patients. Non-invasive CRC diagnostic tests such are either too costly or less reliable than invasive ones. On the other hand, volatile organic compounds (VOCs) are potentially ideal non-invasive biomarkers for CRC detection and monitoring. This review presents the current state-of-the-art VOC-based CRC diagnostics, with a specific focus on recent advancements in biosensor design and application. #MDPIOpenAccess
Sophie Mavrikou’s Post
More Relevant Posts
-
Certified WOS Reviewer & Researcher in Cancer & CRISPR & bioinformatics | looking for collaborations & PhD. Positions Bioinformatics & Cancer
A new dual-amplification CRISPR/Cas biosensing method, Cas13a-12a, has been developed for ultrasensitive detection of miRNA-155, a potential biomarker for early disease diagnosis. This innovative approach leverages the specific nucleic acid recognition abilities of both Cas13a and Cas12a, offering enhanced sensitivity compared to single Cas-based assays. #CRISPR #biosensor #miRNA #biomarker #diagnostics The Cas13a-12a amplification method has shown remarkable sensitivity, with a detection limit of 0.35 fM, significantly lower than that of the Cas13a-based assay alone. It also demonstrates high specificity, effectively distinguishing miRNA-155 from similar interfering miRNAs. The method has been successfully applied to quantify miRNA-155 expression levels in clinical samples from cancer patients, demonstrating its potential for clinical use in early disease diagnosis and identification of tumor patients. #precisionmedicine #personalizedmedicine
To view or add a comment, sign in
-
Freelance Medical Writer and Editor / Evidence-based medicine, precision medicine, unmet treatment needs
I have been seeing the various case studies of people with advanced cancer who tested positive for certain biomarkers, and how they thrived after receiving the right targeted therapies. But are most patients receiving testing for those biomarkers in the first place? This brochure, Molecular Diagnostics in Personalized Cancer Care Best Practices and Overcoming Challenges, not only gives background on precision medicine but also points out the roadblocks to testing. Examples: · Getting enough sample tissue for testing · If testing results even show all biomarkers from a heterogeneous tumor or from metastases as well as primary · Type of testing · Unawareness of the need for testing · Insurance coverage or lack thereof https://lnkd.in/g_-UcWJw
To view or add a comment, sign in
-
🔊 The #Prostate Specific Antigen (PSA) Test Cassette utilizes a #Fluorescence immunoassay to quantitatively detect Prostate Specific Antigen in serum or plasma. This test serves as an important aid in the diagnosis of prostate cancer. By measuring the levels of PSA, a protein produced by the prostate gland, in the blood, healthcare professionals can assess the risk of prostate cancer and monitor its progression. The test result is obtained through the use of a Fluorescence Immunoassay Analyzer, which accurately calculates the PSA levels for diagnostic purposes. This test provides valuable information that assists in the early detection, treatment planning, and monitoring of prostate cancer in patients. 🔎 https://lnkd.in/gme3wtaJ #prostate #prostatehealth #PSA #detection #prostatecancer #health #healthcare #fluorescence #reliable #diagnosis
To view or add a comment, sign in
-
Did you know that cancer is the leading cause of death in Canada? The Pathology Proficiency Testing program at IQMH plays a vital role in ensuring the quality of biomarker testing in medical diagnostic laboratories. The program conducts a comprehensive evaluation of the performance of biomarkers, which helps laboratories improve their quality performance leading to better patient care. Through the evaluation and analysis process, IQMH's Pathology program helps to identify any potential issues and improve the accuracy and reliability of cancer diagnosis and treatment. Together we can improve cancer outcomes for all through prevention strategies, early detection and quality treatment. Learn more here about cancer screening: https://hubs.la/Q02jHVKj0 #WorldCancerDay #MedLab
To view or add a comment, sign in
-
Early detection of cancer cells plays an important role in improving curative outcomes in colorectal cancer (CRC) patients, and the noninvasive screening of DNA methylation biomarkers can contribute to successful early CRC detection. In this paper by Li et al. (2023), BioChain’s high quality genomic DNA samples were used as negative references in a combination method approach to evaluating the methylation status of selected CRC biomarkers. Combination methods such as those used by Li and colleagues can enhance the sensitivity of CRC and precancerous lesion detection and improve patient outcomes. Read more here: https://bit.ly/3zDmxgH #cancercells #biomarkers #DNA #samples #biotech
To view or add a comment, sign in
-
Extracellular Vesicles for Biomarker Detection A non-invasive way to identify and monitor hallmarks of disease from multiple cell types The Walt lab has developed an assay and platform to collect novel biomarkers in the form of extracellular vesicles (EVs) released from cells. As a result, a wider variety of EVs with unmatched quality, quantity, and purity can be obtained. EVs hold incredible value for the scientific and medical communities, as they can provide a better understanding of how disease starts in organs and tissues that are typically inaccessible to diagnostics, such as the brain. This platform can also enable improved and earlier diagnostics of deadly diseases such as ovarian cancer, and can uncover new disease targets to accelerate drug discovery. https://lnkd.in/e8zMBzg8
To view or add a comment, sign in
-
The Impact of Liquid Biopsy in Diagnostics and Treatment Monitoring The field of #liquidbiopsy, though not entirely new, is evolving and transforming cancer diagnostics and treatment monitoring. This innovative approach uses DNA fragments in the bloodstream for early cancer detection, offering non-invasive alternatives to traditional biopsies. Liquid biopsy not only reduces mortality through early detection but also enables ongoing treatment monitoring and disease recurrence surveillance. The focus is on precise, non-invasive, and effective tumor diagnostics. A 2023 article in Nature Review’s Drug Discovery highlights field trends and growth. The diverse applications are showcased, while the escalating interest through the years is illustrated, emphasizing the types and quantity of conducted clinical trials. The article simplifies and sheds light on complex technology applications. #LiquidBiopsy #CancerDetection #HealthInnovation The full article may be found here>> https://lnkd.in/d5XfGqBj
To view or add a comment, sign in
-
👏 We are excited to announce that AmoyDx® Pan Lung Cancer PCR Panel has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for TABRECTA™ (capmatinib) – designed for patients with unresectable, advanced, or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. 🎆 The AmoyDx PLC Panel detects alterations across 11 critical driver genes and identifies actionable mutations in seven of these genes which are directly linked to twelve targeted NSCLC therapies. This approval marks a significant advancement in precision cancer treatment with the potential to significantly enhance patient outcomes. Read the full press release here 👉 : https://lnkd.in/g9BRamEn #PrecisionMedicine #Oncology #NSCLC #LungCancer #Cancer
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for TABRECTATM (Capmatinib)
amoy-diagnostics-co-ltd.shp.so
To view or add a comment, sign in
-
Introducing our new Discover DXRX Data Fact Sheet Series! NSCLC constitutes a staggering 85% of all lung cancer cases. In the US, biomarker testing plays a pivotal role in tailoring treatments. By assessing genetic mutations and protein expressions, clinicians can select optimal therapies, emphasizing the critical importance of understanding the biomarker landscape in NSCLC. Join us on this data-driven journey as we explore the exciting world of DXRX data capabilities! Read our latest fact sheet here: https://lnkd.in/eKCjB2yn #PrecisionMedicine #DXRXData #Biomarkers #NSCLC #Realworlddata
To view or add a comment, sign in
-
🔔 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗟𝗮𝘂𝗻𝗰𝗵! BIOSHARE SOLUTIONS is delighted to launch Internationally ID SOLUTIONS new assay: 𝗜𝗗𝗘𝗦𝗥𝟭, 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗮𝘀𝘀𝗮𝘆 𝗼𝗻 𝘁𝗵𝗲 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝗼𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗮 𝗽𝗮𝘁𝗲𝗻𝘁𝗲𝗱 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝘀𝗲𝗰𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁 𝗿𝗲𝗽𝗼𝗿𝘁. ID SOLUTIONS, the expert in liquid biopsy downstream molecular analysis in oncology, offers innovative and targeted solutions for patients with cancer. IDESR1 is a digital PCR assay, detecting activating ESR1 mutations targeting the hotspot found in exon 8 and the E380Q mutation in plasma samples. COMING NEXT: IDESR1(+): Will detect the same mutations as IDESR1 𝗮𝗻𝗱 “𝗿𝗮𝗿𝗲 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀”: 𝗦𝟰𝟲𝟯𝗣, 𝗩𝟰𝟮𝟮𝗱𝗲𝗹 𝗮𝗻𝗱 𝗞𝟯𝟬𝟯𝗥. ✅ 𝗘𝗮𝘀𝘆-𝘁𝗼-𝘂𝘀𝗲 ✅ 𝗛𝗶𝗴𝗵𝗹𝘆 𝘀𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗲 ✅ 𝗢𝗻𝗲 𝘄𝗲𝗹𝗹 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 ✅ 𝗣𝗮𝘁𝗲𝗻𝘁𝗲𝗱 “𝗜𝗖𝗘” 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝘍𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺. Not for use in diagnostic procedures. Find out more: https://lnkd.in/dWEg2Wg2 Do not hesitate to contact us: https://lnkd.in/dEWpjvp6 #biosharesolutions #idsolutions #idsolutionsoncology #esr1 #oncology #breastcancer #dpcr #multiplex #montpellier #marseille #distribution #personalisedmedicine #cancer
To view or add a comment, sign in